132 related articles for article (PubMed ID: 38091504)
1. Screening and Characterization of Allosteric Small Molecules Targeting Bruton's Tyrosine Kinase.
Kueffer LE; Lin DY; Amatya N; Serrenho J; Joseph RE; Courtney AH; Andreotti AH
Biochemistry; 2024 Jan; 63(1):94-106. PubMed ID: 38091504
[TBL] [Abstract][Full Text] [Related]
2. Deletion within the Src homology domain 3 of Bruton's tyrosine kinase resulting in X-linked agammaglobulinemia (XLA).
Zhu Q; Zhang M; Rawlings DJ; Vihinen M; Hagemann T; Saffran DC; Kwan SP; Nilsson L; Smith CI; Witte ON; Chen SH; Ochs HD
J Exp Med; 1994 Aug; 180(2):461-70. PubMed ID: 7519238
[TBL] [Abstract][Full Text] [Related]
3. Differential impact of BTK active site inhibitors on the conformational state of full-length BTK.
Joseph RE; Amatya N; Fulton DB; Engen JR; Wales TE; Andreotti A
Elife; 2020 Nov; 9():. PubMed ID: 33226337
[TBL] [Abstract][Full Text] [Related]
4. Rapid tyrosine phosphorylation and activation of Bruton's tyrosine/Tec kinases in platelets induced by collagen binding or CD32 cross-linking.
Oda A; Ikeda Y; Ochs HD; Druker BJ; Ozaki K; Handa M; Ariga T; Sakiyama Y; Witte ON; Wahl MI
Blood; 2000 Mar; 95(5):1663-70. PubMed ID: 10688822
[TBL] [Abstract][Full Text] [Related]
5. An SH3-binding site conserved in Bruton's tyrosine kinase and related tyrosine kinases mediates specific protein interactions in vitro and in vivo.
Yang W; Malek SN; Desiderio S
J Biol Chem; 1995 Sep; 270(35):20832-40. PubMed ID: 7657668
[TBL] [Abstract][Full Text] [Related]
6. Molecular and structural characterization of five novel mutations in the Bruton's tyrosine kinase gene from patients with X-linked agammaglobulinemia.
Saha BK; Curtis SK; Vogler LB; Vihinen M
Mol Med; 1997 Jul; 3(7):477-85. PubMed ID: 9260159
[TBL] [Abstract][Full Text] [Related]
7. Structure of the PH domain and Btk motif from Bruton's tyrosine kinase: molecular explanations for X-linked agammaglobulinaemia.
Hyvönen M; Saraste M
EMBO J; 1997 Jun; 16(12):3396-404. PubMed ID: 9218782
[TBL] [Abstract][Full Text] [Related]
8. Signalling of Bruton's tyrosine kinase, Btk.
Mohamed AJ; Nore BF; Christensson B; Smith CI
Scand J Immunol; 1999 Feb; 49(2):113-8. PubMed ID: 10075013
[TBL] [Abstract][Full Text] [Related]
9. Activation mechanism and steady state kinetics of Bruton's tyrosine kinase.
Dinh M; Grunberger D; Ho H; Tsing SY; Shaw D; Lee S; Barnett J; Hill RJ; Swinney DC; Bradshaw JM
J Biol Chem; 2007 Mar; 282(12):8768-76. PubMed ID: 17264076
[TBL] [Abstract][Full Text] [Related]
10. Activation of Bruton's tyrosine kinase (BTK) by a point mutation in its pleckstrin homology (PH) domain.
Li T; Tsukada S; Satterthwaite A; Havlik MH; Park H; Takatsu K; Witte ON
Immunity; 1995 May; 2(5):451-60. PubMed ID: 7538439
[TBL] [Abstract][Full Text] [Related]
11. Pharmacophore modeling and virtual screening in search of novel Bruton's tyrosine kinase inhibitors.
Sharma A; Thelma BK
J Mol Model; 2019 Jun; 25(7):179. PubMed ID: 31172362
[TBL] [Abstract][Full Text] [Related]
12. SH3 domain of Bruton's tyrosine kinase can bind to proline-rich peptides of TH domain of the kinase and p120cbl.
Patel HV; Tzeng SR; Liao CY; Chen SH; Cheng JW
Proteins; 1997 Dec; 29(4):545-52. PubMed ID: 9408950
[TBL] [Abstract][Full Text] [Related]
13. Bruton tyrosine kinase (BTK) in X-linked agammaglobulinemia (XLA).
Vihinen M; Mattsson PT; Smith CI
Front Biosci; 2000 Dec; 5():D917-28. PubMed ID: 11102316
[TBL] [Abstract][Full Text] [Related]
14. BTK, the tyrosine kinase affected in X-linked agammaglobulinemia.
Vihinen M; Mattsson PT; Smith CI
Front Biosci; 1997 Jan; 2():d27-42. PubMed ID: 9159207
[TBL] [Abstract][Full Text] [Related]
15. Identification of Bruton's tyrosine kinase (Btk) gene mutations and characterization of the derived proteins in 35 X-linked agammaglobulinemia families: a nationwide study of Btk deficiency in Japan.
Hashimoto S; Tsukada S; Matsushita M; Miyawaki T; Niida Y; Yachie A; Kobayashi S; Iwata T; Hayakawa H; Matsuoka H; Tsuge I; Yamadori T; Kunikata T; Arai S; Yoshizaki K; Taniguchi N; Kishimoto T
Blood; 1996 Jul; 88(2):561-73. PubMed ID: 8695804
[TBL] [Abstract][Full Text] [Related]
16. Noncatalytic Bruton's tyrosine kinase activates PLCγ
Wist M; Meier L; Gutman O; Haas J; Endres S; Zhou Y; Rösler R; Wiese S; Stilgenbauer S; Hobeika E; Henis YI; Gierschik P; Walliser C
J Biol Chem; 2020 Apr; 295(17):5717-5736. PubMed ID: 32184360
[TBL] [Abstract][Full Text] [Related]
17. B-cell antigen receptor stimulation activates the human Bruton's tyrosine kinase, which is deficient in X-linked agammaglobulinemia.
de Weers M; Brouns GS; Hinshelwood S; Kinnon C; Schuurman RK; Hendriks RW; Borst J
J Biol Chem; 1994 Sep; 269(39):23857-60. PubMed ID: 7929028
[TBL] [Abstract][Full Text] [Related]
18. Oral administration of Bruton's tyrosine kinase inhibitors impairs GPVI-mediated platelet function.
Rigg RA; Aslan JE; Healy LD; Wallisch M; Thierheimer ML; Loren CP; Pang J; Hinds MT; Gruber A; McCarty OJ
Am J Physiol Cell Physiol; 2016 Mar; 310(5):C373-80. PubMed ID: 26659727
[TBL] [Abstract][Full Text] [Related]
19. G Protein beta gamma subunits act on the catalytic domain to stimulate Bruton's agammaglobulinemia tyrosine kinase.
Lowry WE; Huang XY
J Biol Chem; 2002 Jan; 277(2):1488-92. PubMed ID: 11698416
[TBL] [Abstract][Full Text] [Related]
20. Bruton's tyrosine kinase (Btk) associates with protein kinase C mu.
Johannes FJ; Hausser A; Storz P; Truckenmüller L; Link G; Kawakami T; Pfizenmaier K
FEBS Lett; 1999 Nov; 461(1-2):68-72. PubMed ID: 10561498
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
